Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Clinical trial NCT06141460 · RECRUITING
Trial details
- NCT number
- NCT06141460
- Sponsor
- Shanghai Refreshgene Technology Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-12
- Primary completion
- 2026-04-15
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.